SPRINT-MS is a large-scale longitudinal phase II trial including 27 3T MRI scanners to evaluate the treatment of progressive multiple sclerosis with Ibudilast. DTI measures showed high reproducibility in a longitudinal multicenter study, making it appropriate for use as a biomarker. The longitudinal design of the SPRINT-MS trial is expected to mitigate the systematic influence of SNR on DTI, but the observed trend may be useful as a correction factor in cross-sectional studies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords